Peptides for inflammation: KPV, BPC-157, TB-500 and what they do

Acute inflammation is the response to injury or infection and resolves on its own. Chronic low grade inflammation is the background elevation in markers like CRP that comes with obesity, aging and metabolic disease. Immune mediated disease, like inflammatory bowel disease, rheumatoid arthritis or psoriasis, is a third thing. Each has a location too: a tendon, a patch of skin, the gut lining, or the whole body. A question about peptides for inflammation needs a where and a what kind, because the animal models behind these compounds are nearly all local and nearly all acute or immune mediated.

One aside sets the scale. The only peptides with human data on an inflammatory marker are the GLP-1 drugs, which lower CRP in their trials through weight loss rather than any direct anti-inflammatory action. None of the four compounds on this page has a human measurement of anything comparable.

KPV is lysine, proline and valine, the last three amino acids of alpha-MSH, and it carries the hormone's anti-inflammatory effect without its pigmentation effect. It enters cells and stops NF-kB, the master switch for inflammatory gene expression, from moving into the nucleus, which cuts production of TNF-alpha, IL-6 and IL-1 beta, and it does not appear to need the classic melanocortin receptors to do it. In the gut it is carried into inflamed intestinal cells by the PepT1 transporter, which is upregulated during inflammation, and that is the rationale for oral dosing.

The evidence is mouse colitis, where oral KPV reduced inflammation, weight loss and tissue damage, with the best results from nanoparticle formulations that protect it through the gut and that most vendors do not sell. Mouse dermatitis models improved; arthritis, uveitis and lung injury each have one mouse study. There are no human trials and no human safety data; the compound page rates it preclinical. Reported protocols are 500 mcg to 1 mg orally once or twice daily on an empty stomach for gut use, 250 to 500 mcg subcutaneously or nasally for systemic use, and a thin layer of low concentration cream for skin. Courses run 4 to 8 weeks or around flares. The two cautions are an active infection, where broad NF-kB suppression could blunt a needed response, and immunosuppressants or biologics, where the combination has never been studied.

BPC-157 is not primarily an anti-inflammatory; its page describes a repair compound whose anti-inflammatory effect comes with the territory. Its deepest animal literature is the gut: protection of the stomach lining against NSAIDs and alcohol, faster ulcer healing, and better outcomes in rodent colitis and fistula models, with involvement of the nitric oxide system and the mucosal barrier. At injury sites it raises VEGF and drives capillary growth and cell migration through the FAK-paxillin pathway, and inflammation falls as repair proceeds. The small early phase human trials in ulcerative colitis were described as favorable and never published as full controlled studies.

Reported doses are 250 to 500 mcg once or twice daily, oral for gut complaints and subcutaneous for tissue, with oral doses taken away from food so the peptide contacts the lining. Its cautions are the angiogenesis concern with any existing tumor, WADA status, and unknown effects on clotting. BPC-157 vs KPV separates repair from inflammation control, and the BPC-157 and KPV stack is the gut protocol that uses both.

Full length thymosin beta-4 reduces inflammatory cytokine release and lowers apoptosis in stressed cells while it recruits progenitor cells into damaged tissue. The closest thing to human anti-inflammatory data in this group is the phase 2 program of thymosin beta-4 eye drops for dry eye and neurotrophic keratopathy, inflammatory surface conditions where the drops showed modest benefit. That used the full 43 amino acid protein. TB-500 as sold is usually the 7 amino acid fragment with the actin binding motif, assumed to carry the effects, likely lacking some, and with no human data. It works systemically; protocols load at 2 to 2.5 mg twice weekly. The cautions are the tumor concern, since thymosin beta-4 is expressed in many cancers, WADA status, and fatigue after larger doses.

GHK-Cu gets onto inflammation lists through gene expression work showing it suppresses genes tied to inflammation and fibrosis while activating repair and antioxidant genes, partly by delivering copper to enzymes like superoxide dismutase. Its human trials are topical skin studies with cosmetic endpoints. Injectable GHK-Cu at 1 to 2 mg daily has no human data, stings, and is off limits with any copper disorder. For an inflamed patch of skin, a patch tested topical at 0.5 to 3 percent is the version with any basis.

Oral KPV and oral BPC-157 act on the gut lining on contact. The KPV page is explicit that oral doses stay in the gut and are cleared with transit, so a capsule is a gut treatment and not a treatment for a shoulder or a blood marker. Injected KPV and TB-500 are systemic. Topical KPV and GHK-Cu treat the skin they are applied to. Picking a route picks the target, and a goal like lowering systemic inflammation has no endpoint at home except CRP bloodwork, which nobody has shown any of these compounds move.

The gut versus joint distinction follows from the data. Gut inflammation has multiple mouse colitis models for KPV, extensive BPC-157 gut work, and a biological reason oral dosing reaches the target, because PepT1 is upregulated in inflamed intestinal cells. Joint inflammation has a single mouse study for KPV and nothing degenerative for BPC-157, as peptides for joint pain sets out. Gut use stands on the best of a thin evidence base; joint use is extrapolation from tendon repair.

KLOW is a forum and vendor nickname for KPV, GHK-Cu, BPC-157 and TB-500 together, on the logic that KPV handles inflammation, BPC-157 repair, TB-500 cell migration and GHK-Cu collagen. GLOW is the same without KPV, and the Wolverine stack is BPC-157 and TB-500 alone. None are products or regulated protocols, and there is no data on any combination; the doses on the KLOW stack and GLOW stack pages are the individual reported ranges run at the same time.

The one live argument is whether they belong in the same vial. Some argue that GHK-Cu's copper ion and its preferred pH of around 5 to 6.5 can degrade BPC-157 and TB-500 in a shared solution, and all three compound pages say to inject GHK-Cu separately. Vendors sell pre-mixed blends anyway, users report using them, and there is no published stability data either way. A separate syringe also makes GHK-Cu's stinging easy to trace.

No controlled human trial has shown any of these compounds reducing CRP, cytokines, disease activity in inflammatory bowel disease, eczema severity, arthritis scores or any other inflammatory outcome. The BPC-157 colitis pilots were never fully published, the thymosin beta-4 eye data is for the full protein, and KPV has never been given to a human in a trial. Inflammatory symptoms are also strongly placebo responsive, which the compound pages handle with a simple test: run 4 to 8 weeks, stop, and see whether the symptoms come back.

The cautions are specific. Anyone with an active infection pauses KPV. Anyone on an immunosuppressant or a biologic has no data on adding KPV and should raise it with the prescriber. Anyone with a cancer history avoids BPC-157 and TB-500. Anyone with Wilson disease avoids GHK-Cu. Tested athletes avoid BPC-157 and TB-500 as WADA prohibited. And nobody with diagnosed inflammatory bowel disease or rheumatoid arthritis should use these in place of treatment. Are peptides safe and peptide side effects cover the class level risks.